The prevalence of bothersome overactive bladder (OAB) symptoms in men does not differ notably from that in women, but men are much less likely to receive treatment with OAB medications. Men's rates of continuation of OAB medications and progression to third-line OAB treatments (botulinum toxin or neuromodulation) remain unknown. This study investigated use of third-line OAB treatment in a real-word setting using a nationally-representative claims database.
INTRODUCTION AND OBJECTIVES:
The prevalence of bothersome overactive bladder (OAB) symptoms in men does not differ notably from that in women, but men are much less likely to receive treatment with OAB medications. Men's rates of continuation of OAB medications and progression to third-line OAB treatments (botulinum toxin or neuromodulation) remain unknown. This study investigated use of third-line OAB treatment in a real-word setting using a nationally-representative claims database.
METHODS: A retrospective cohort study of adult men diagnosed with non-neurogenic OAB between January 1, 2013 and September 30, 2014 was conducted using the Truven MarketScan Commercial Claims and Encounters Database. Men included in analyses had at least two claims on separate encounter dates with an OAB ICD-9 diagnosis code and were age 63 years or younger at their first claim. Men were excluded if they lacked continuous health insurance plan enrollment for at least one year before and two years following OAB diagnosis.
RESULTS: A total of 26,100 men were included; 3,492 (13.4%) were prescribed second-line OAB therapy (medications) within two years of OAB diagnosis. The median time from diagnosis to an OAB medication prescription was 44 days. Of the men prescribed OAB medications, 29% (1,004) maintained their prescription two years later. Within two years of their first OAB medication prescription, 50 men (1.4%) had undergone third-line OAB treatment, with a median time from diagnosis to third-line therapy of 281 days.
CONCLUSIONS: OAB may be undertreated in men, according to low rates of medication prescriptions for second-line therapy. Similar to women, this undertreatment is likely compounded by the frequent and rapid discontinuation of such medications, as well as low rates of progression from second-line to third-line therapy with either botulinum toxin or neuromodulation. Further studies on the diagnostic and treatment patterns of men with OAB are warranted to identify the factors underlying this undertreatment. 
Frailty is an important predictor of poor medical and surgical outcomes among older individuals, however, the impact of frailty on second-and third-line treatments for overactive bladder (OAB) in frail older adults remains unknown. The purpose of this study is to examine the effect of frailty on treatment outcomes in older adults starting pharmacotherapy, onabotulinumtoximA and sacral neuromodulation.
METHODS: This is a prospective study of men and women !60 years starting pharmacotherapy, onabotulinumtoxinA or sacral neuromodulation for OAB. Subjects were administered a questionnaire at baseline and again at 1-and 3-months. Frailty was assessed at baseline using the timed up and go (TUG) test (whereby a TUG time of !12 seconds was considered to be slow, or frail). Response to treatment was assessed using the overactive bladder symptom score (OABSS) and the OAB-q SF (both bother and HRQOL subscales). Information on side effects/adverse events was also collected. Mixed effects linear modeling was used to model changes in outcomes over time both within and between groups.
RESULTS: A total of 45 subjects (22 pharmacotherapy; 12 onabotulinumtoxinA; 11 sacral neuromodulation) enrolled in the study, 40% (N[18) of whom had a TUG !12 seconds. There were no differences in responses to baseline OAB questionnaires between TUG groups (all p-values >0.05). Both TUG groups demonstrated improvement in OAB symptoms over time and there were no statistically significant differences in these responses per group (all p-values >0.05) (Figure) . Similar trends were found for both OAB-q bother and OAB-q HRQOL questionnaire responses. Side effects and adverse events were comparable between groups (all p>0.05).
CONCLUSIONS: Adults !60 years of age starting second-and third-line treatments for OAB, regardless of TUG time, demonstrated improvement in OAB symptoms at 3 months. These findings suggest that frail older adults receive comparable benefit and similar rates of side effects compared to less frail individuals, supporting the use of second-and third-line OAB treatments in properly selected older adults.
